Buffett firm slashes J&J stake by 95%; Sanofi shops Israel for consumer health company;

@FiercePharma: Slovenia's Krka expects 2012 profits to fall short, but sees 6% sales hike in 2013; plans hiring, new plants. Article | Follow @FiercePharma

> FDA Commissioner Margaret Hamburg clashed with lawmakers on Capitol Hill yesterday, as she called for clearer FDA authority to regulate compounding pharmacies. Report

> Warren Buffett's Berkshire Hathaway ($BRK.B) unloaded 95% of its stake in Johnson & Johnson ($JNJ) in its latest selloff of the stock. Report

> The U.K.'s cost-effectiveness watchdog gave a final rejection to Pierre Fabre's bladder cancer drug Javior. Report

> Sanofi's ($SNY) Israeli unit is shopping for a consumer healthcare company there, aiming for a deal in the "several tens of millions." Report

> Slovenia's Krka saw net profits drop by 3%, but officials expect a 6% increase in sales for 2013, to €1.2 billion ($1.5 billion), and plan new hires and new plants at home and in Russia. Report

Medical Device News

 @FierceMedDev: As advocates fight to repeal the device tax, we take a detailed look at how the 2.3% charge would work. Special Report | Follow @FierceMedDev

 @MarkHFierce: Hansen Medical, maker of the Magellan Surgical Robot, raised $10M in a new offering. More | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics broke ground on the first phase of its $300M Indianapolis expansion. News | Follow @DamianFierce

> Study: CardioDx's test helps guide cardiology decisions. Story

> Report: U.S. government incentives will spur robust infusion pump sales. Item

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: PPD secures adaptive trials software as clinical studies evolve. More | Follow @FierceBiotech

 @JohnCFierce: After FDA rejection, Bristol-AstraZeneca team wins E.C. OK for diabetes drug dapagliflozin--new hope for SGLT2 drugs. News | Follow @JohnCFierce

 @RyanMFierce: 10 trends in diagnostics from FierceBiotech. #1: Companion Dx. Special Report | Follow @RyanMFierce

> Sanofi's new CSO to steer R&D reinvention drive from Cambridge, MA office. Report

> Troubled Tranzyme reports another key clinical trial failure. News

> Upstart Valor launches with plans to develop armed antibody cancer drugs. Article

Pharma Manufacturing News

> Call for counterfeit drug treaty gets group banned from WHO event. Article

> Regeneron invests $80 million in plant, office project. News

> Promega expands with new China plant. Item

> Genzyme manufacturing upgrades again paying off. Story

Vaccines News

 @AlisonBFierce: Inovio Pharmaceuticals, a developer of synthetic vaccines, expanded its existing license agreement with UPenn. More | Follow @AlisonBFierce

> FDA: Dynavax's Heplisav effective against hepatitis B. Report

> Meningitis vaccine ruled safe for warm storage. Article

> Takeda sets sights on the vaccine market. More

> GSK's rotavirus vaccine selected for British program. News

> GSK reports lackluster PhIII malaria vaccine data. Story

And Finally... Beta blockers, used to treat high blood pressure, are considered performance-enhancers in professional golf. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.